Anticoagulant modulation of inflammation in severe sepsis
Authors:
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 4 (2) , 105-15
Abstract
Inflammation and coagulation are so tightly linked that the cytokine storm which accompanies the development of sepsis initiates thrombin activation and the development of an intravascular coagulopathy. This review examines the interaction between the inflammatory and coagulation cascades, as well as the role of endogenous anticoagulants in regulating this interaction and dampening the activity of both pathways. Clinical trials attempting to improve outcomes in patients with severe sepsis by inhibiting thrombin generation with heparin and or endogenous anticoagulants are reviewed. In general, these trials have failed to demonstrate that anticoagulant therapy is associated with improvement in mortality or morbidity. While it is possible that selective patients who are severely ill with a high expected mortality may be shown to benefit from such therapy, at the present time none of these anticoagulants are neither approved nor can they be recommended for the treatment of sepsis.Keywords
This publication has 53 references indexed in Scilit:
- Antithrombin and mortality in severe pneumonia patients with sepsis‐associated disseminated intravascular coagulation: an observational nationwide studyJournal of Thrombosis and Haemostasis, 2014
- Thrombosis as an intravascular effector of innate immunityNature Reviews Immunology, 2012
- Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregressionThe Lancet Infectious Diseases, 2012
- Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)*Critical Care Medicine, 2009
- Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin ComplexesArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Novel cell death program leads to neutrophil extracellular trapsJournal of Cell Biology, 2007
- High-Dose Antithrombin Therapy for Sepsis: Mechanisms of ActionShock, 2002
- A Comparative Double-Blind Randomized Trial of Activated Protein C and Unfractionated Heparin in the Treatment of Disseminated Intravascular CoagulationInternational Journal of Hematology, 2002
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia.Journal of Experimental Medicine, 1994